

biotechne®

Asuragen®

Bringing Exosome-Powered, High-Sensitivity *ESR1* Mutation Testing to qPCR

QuantideX®


qPCR *ESR1* exoMutation Kit†

ExoLution™ Plus cfDNA + exoRNA Sample Preparation Kit*

ESR1 mutations are a primary cause of endocrine therapy resistance in hormone receptor-positive (HR+) metastatic breast cancer (mBC)¹. Although rare in treatment naïve individuals, these mutations are prevalent in up to 40% of mBC cases treated with endocrine therapy and ultimately result in disease progression¹. Ongoing clinical trials aim to demonstrate the benefits of adjusting course of treatment upon *ESR1* mutation detection². Asuragen has developed the first, multi-analyte, qPCR-based, liquid biopsy assay for the detection of *ESR1* mutations from plasma, empowering molecular laboratories to participate in this new frontier of clinical research and push the boundaries of conventional qPCR. The QuantideX qPCR *ESR1* exoMutation Kit, paired with the ExoLution™ Plus cfDNA + exoRNA Sample Preparation Kit, leverages proprietary chemistries from Exosome Diagnostics™ to co-isolate cfDNA + exoRNA in a single workflow and is designed to provide highly sensitive detection of the 11 most prevalent *ESR1* variants in plasma, offering a novel approach to achieving more meaningful breast cancer insights.

Interested in becoming an Early Access Site?

Enrollment for early access sites will begin in Spring 2024. Interested in partnering with us?



Bio-Techne® | R&D Systems™ | Novus Biologicals™ | Tocris Bioscience™ | ProteinSimple™ | ACD™ | ExosomeDx™ | Asuragen®

†For Research Use Only. Not for use in diagnostic procedures. Trademarks and registered trademarks are the property of their respective owners.

*This product is under development; performance characteristics and final product features to be determined.

1. Breast Cancer Res. 2021 Aug 15;23(1):85. 2. Lancet Oncol. 2022 Nov;23(11):1367-1377.